CovAb™

SARS-CoV-2 Ab Test

CovAb™ Oral Fluid Antibody Test for Assessment of Immune Response to Pfizer-BioNTECH Vaccination

Clinical Study

- A total of 68 subjects who received the Pfizer BioNTECH vaccine were tested at 3 timepoints with the CovAb™ antibody test to assess levels of anti-SARS-CoV-2 S1/RBD domain antibodies
  - 68 subjects were tested on the day of vaccination, 4 weeks after the 1st dose, on the day of the second dose, and 2 weeks after the second dose
  - 20 subjects were tested 6-7 months after the second dose of vaccine

SARS-CoV-2 S1/RBD domain antibody status with CovAb™ at first dose of vaccine





Antibody-positive
Antibody-negative

Positive
70 RU
Negative

SARS-CoV-2 S1/RBD domain antibody status with CovAb™ at 4 weeks after first dose of vaccine







SARS-CoV-2 S1/RBD domain antibody status at 2 weeks after second dose of vaccine





Positive
70 RU
Negative

SARS-CoV-2 S1/RBD domain antibody status first and second dose of vaccine



4 weeks after 1st dose

2 weeks after 2nd dose

Positive
70 RU
Negative

SARS-CoV-2 S1/RBD domain antibody status 6-7 months after the second dose of vaccine





Antibody-positive
Antibody-negative



Summary

- 3% (2/68 subjects) of subjects were positive for SARS-CoV-2 S1 domain antibodies on day one of the first dose of vaccination, presumably representing asymptomatic COVID-19-positive individuals.
- 32% (22/68) of subjects had detectable levels of SARS-CoV-2 S1 domain antibodies at 4 weeks after the first dose of vaccine.
- 94% (64/68) of subjects were positive for SARS-CoV-2 S1 domain antibodies at 2 weeks after the second dose of vaccine.
- 45% (9/20) of subjects were negative for SARS-CoV-2 S1 domain antibodies at 6-7 months post-vaccination.
- There was an average 85% of decrease in antibody titer at 6-7 months post-vaccination.

Conclusions

- The first dose of vaccine elicited a detectable antibody response in 32% of subjects after 4 weeks
- The second dose of vaccine elicited moderate to high levels of antibodies in 94% of subjects after 2 weeks
- At 6-7 months post-vaccination, there was an average 85% reduction in antibody levels and 45% of subjects had no detectable antibodies
- Subjects with no detectable antibodies are likely to be at greater risk for breakthrough infection
- Monitoring antibody levels with CovAb™ helps to determine the timing of booster shots and preventive measures

CovAb™

SARS-CoV-2 Ab Test

THANK YOU